15,041 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Resonant Capital Advisors LLC

Resonant Capital Advisors LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 15,041 shares of the biopharmaceutical company's stock, valued at approximately $1,261,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Manning & Napier Advisors LLC purchased a new stake in Gilead Sciences during the second quarter valued at approximately $25,328,000. Legal & General Group Plc increased its stake in shares of Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock worth $851,743,000 after purchasing an additional 93,068 shares in the last quarter. GSA Capital Partners LLP bought a new position in Gilead Sciences in the 1st quarter worth $462,000. Brookstone Capital Management lifted its position in Gilead Sciences by 751.1% during the first quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company's stock valued at $9,322,000 after purchasing an additional 112,305 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Gilead Sciences by 13.1% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company's stock valued at $19,630,000 after purchasing an additional 33,162 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock valued at $3,033,340 in the last ninety days. Insiders own 0.16% of the company's stock.

Gilead Sciences Price Performance

Shares of GILD stock traded down $0.64 on Friday, reaching $86.72. The company's stock had a trading volume of 4,365,082 shares, compared to its average volume of 7,080,318. The stock's fifty day simple moving average is $81.06 and its 200-day simple moving average is $72.82. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The company has a market capitalization of $108.04 billion, a price-to-earnings ratio of 240.89, a price-to-earnings-growth ratio of 2.98 and a beta of 0.18. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Analysts forecast that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were given a dividend of $0.77 per share. The ex-dividend date was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.55%. Gilead Sciences's dividend payout ratio (DPR) is presently 855.56%.

Analysts Set New Price Targets

GILD has been the topic of several recent research reports. Truist Financial raised their price objective on Gilead Sciences from $82.00 to $83.00 and gave the stock a "hold" rating in a research note on Thursday, August 15th. Barclays raised their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the stock an "equal weight" rating in a research note on Monday, October 7th. Royal Bank of Canada upped their price target on shares of Gilead Sciences from $74.00 to $75.00 and gave the stock a "sector perform" rating in a research report on Friday, October 4th. Wells Fargo & Company raised shares of Gilead Sciences from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $78.00 to $100.00 in a research note on Monday, October 7th. Finally, Raymond James upgraded shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 target price on the stock in a research note on Monday, July 8th. Ten analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $86.37.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.